Nrxn1/README.md

Nrxn1 Knock-out

Longitudinal study monitoring the progression of any electrophysiological phenotype related to sensory processing in the Nrxn1α knock-out model. The study contains two data sets (raw):

• Charaterization (folder: charact) contains: 4-hour recordings at 10 weeks and 22 weeks, VEP and AEP at 10, 14, 18 and 22 weeks of age.
• Arbaclofen (folder: arbaclofen) contains: 24-hour recordings at 8 weeks and 22 weeks, cross-over study VEP and AEP with 2 mg/kg arbaclofen at 8 weeks and 22 weeks.

File types

The recordings were made in TainiLive. The recording files are of the .edf+ type, meta data is provided as .yaml files and screenshots of the recording logs are available containing the exact transmitter frequency of each recording. The 24-hour recordings contain data from motion sensors recorded with Spike2 (CED) as .smrx format.

Characterization

Electrode configuration

Electrodes implanted bilaterally over visual (AP -4, ML +- 2.5) (ch 3 & 14) and auditory cortices (AP -2.5, ML +- 3.5) (ch 4 & 12) and unilaterally over PFC (AP 2.58 ML -1.57) (ch13). Two EMGs in neck muscles (ch 8 & 11) and reference over the cerebellum.

Recording specifications

Due to software updates during the study the sampling frequency is not the same in all recordings

• Sampling frequency: 19525 Hz
• Low-pass filter: 9700 Hz
• High-pass filter: 0.35 Hz

A few files were recorded with the sampling frequency: 2789.3 Hz

• VEP 3: 55970, 55971, 55963, 55964

Genotypes

The genotype of the animal is presented below:

Batch #	WT	Het	Hom
1	51333	51334	51372
	51346	51341	51383
	51355	51343	51389
	51363	51344	51391e
	51375	51345	51403
	51413	51351	51405
		51352
2	55970	55949	55948
	55979	55963	55964
	55984	55983	55971
		55985	55978
3	57738	57767	57737
	57753	57781	57752
	57760		57762
	57763		57766
	57782
Total n	14	13	13(14)

e - poor signal at last recording

Arbaclofen study

Longitudinal study of how acute administration of arbaclofen affect the Nrxn1α knock-out model. Arbaclofen (2 mg/kg) i saline was administered in a cross-over design at 8 weeks and 22 weeks of age.

The data includes a dose adjustment pilot (folder: VEP/additional/dose-response) with doses 3 mg/kg and 4 mg/kg and VEP gating at 30 weeks (folder: VEP/additional/aging).

Electrode configurations

Electrode configuration was the same as above for most of the animals, but for animals: 74979,74980,74981,74983,75023 The electrode configuration was as follows:

Electrodes implanted bilaterally over visual (AP -4, ML +- 2.5) (ch 14 & 4) and auditory cortices (AP -2.5, ML +- 3.5) (ch 13 & 5) and unilaterally over PFC (AP 2.58 ML -1.57) (ch 3). Two EMGs in neck muscles (ch 8 & 11) and ref over the cerebellum.

Randomization

First recording (visual and auditory) of first time point:

• Arb: 75031, 74960, 74959, 74965, 74985, 74930, 74931, 74988, 74924, 74968, 75024
• Vehicle: 74979, 74980, 74981, 74983, 75032, 75033, 74958, 74966, 74967, 74986, 74989, 75023
• second recordings, vice versa

First recording of second time point:

• Arb: 74979, 75032, 75033, 74960, 74958, 74959, 74966, 74967, 74930, 74989, 74968
• Vehicle: 74980, 74981, 74983, 75031, 74965, 74985, 74931, 74988, 74924, 75024, 75023
• second recordings, vice versa

Recording specifications

• Sampling rate: 1084.7 Hz
• Low-pass filter: 9700 Hz
• High-pass filter: 0.35 Hz

Genotypes

WT	Het	Hom
74959	74924	74930
74967	74960	74931
74968	74965	74958
74986e	74966	74981
74988	74979	74983
75024	74980	74985
	74989	75023
	75032	75031
		75033
n=6	8	9

e - only first time point